Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.

Funder: National Cancer Institute

Funding period
USD 1.6 M
Funding amount
Abstract
Bladder cancer is one of the most common forms of cancer in North America. Most often, bladder cancer presents as superficial disease, which is treatable through surgical resection, but is also associated with recurrence rates of up to 70%. Thus, patients must be monitored at regular intervals following resection of the tumor to assess for recurrence. This monitoring is done by cystoscopy, which requires a scope to be inserted into the urethra and into the bladder to visually inspect the bladder wall, and is associated with significant patient discomfort, poor compliance to the recommended screening schedule, and high screening costs as cystoscopy must be performed by a physician. Indeed, the cost of screening and surgical interventions makes bladder cancer the most expensive cancer to treat on a per patient basis. Finally, small masses are likely to be missed by visual inspection, resulting in sub-optimal assessment of recurrence. The bladder cancer community has recognized the problems with cystoscopy as the primary screening technique, resulting in a number of attempts to develop urine based assays to more accurately assess the presence of recurrent disease. These assays have looked for the presence of cancer cells or specific proteins associated with cancer. Unfortunately, most of these tests lack specificity, as they measure processes that may be present in other non-cancer conditions such as infection or kidney stone disease, or lack sensitivity, as they measure events that are present only in a subset of bladder cancer patients, usually high-grade disease. As a result, none of the urine based tests currently available are recommended by the American Urological Association as a primary screening tool. We propose to take advantage of recent technological advances and our understanding of the molecular processes involved in bladder cancer to develop a comprehensive screening panel that assays the urine of patients. This technique is non-invasive, and we estimate that we will be able to detect more 90-95% of all bladder cancer patients, giving us high sensitivity to detect recurrent disease, including patients with low grade disease who are missed by current screening techniques. We have performed preliminary tests on patient samples and accurately detected tumors in greater than 90% of such patients. We have also performed testing in normal controls, and none have tested positive for the presence of cancer. Thus, we believe that the test will also have high specificity. Our current proposal aims to build upon our preliminary data by expanding the panel of biomarkers that we assay for even greater coverage, and to investigate technical enhancements to improve the sensitivity. This approach will lead to the development of a non-invasive screening assay that will have excellent sensitivity and specificity at a lower price point than current screening techniques. Thus, the successful development of our assay will improve patient outcomes while reducing the cost burden on the health care system.
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Health Services

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Prevention

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • HRCS RAC

    4.2 Evaluation of markers and technologies

  • HRCS RAC

    7.3 Management and decision making

  • Health Research Areas

    Clinical

  • Broad Research Areas

    Clinical Medicine and Science